PCN Insights, News, Videos, and More

Stimulant use for the treatment of attention-deficit/hyperactivity disorder (ADHD) was associated with higher occurrence of psychotic symptoms, psychotic disorders, and bipolar disorder (BD), according to a systematic review.

In this video taken on-site at the 2025 Psych Congress, Steering Committee Member Amber Hoberg, PMHNP-BC, walks clinicians through her approach to managing some common comorbid conditions that may impact schizophrenia patients.

Discussions of ethical intervention, patient autonomy, and justice reform took center stage during the keynote address at the 2025 Psych Congress on Wednesday evening.

Clinician use of a specific weighted multigene pharmacogenomic (PGx) test significantly improved outcomes in adult patients with major depressive disorder (MDD) with at least 1 treatment failure, according to meta-analysis results.

Sleep–wake disorders are common, clinically significant, and too often overlooked in psychiatric practice. In this episode, Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating conditions such as insomnia,...

The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.

Cannabis products that contained high concentrations of delta-9-tetrahydrocannabinol (THC) were associated with psychosis, schizophrenia, and cannabis use disorder (CUD), according to a systematic review.

In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, provides an overview of recent developments in reimbursement policies for telehealth services.

Fibromyalgia is more than widespread pain—it’s a condition that blurs the lines between psychiatry, medicine, and the human experience. In this episode, Drs. Rakesh Jain and Craig Chepke discuss a newly approved treatment, explore why...

In this video, Psych Congress Steering Committee Member Brooke Kempf, PMHNP-BC, discusses how the development of muscarinic-targeting treatments is shaping the future of schizophrenia care.